Physician profile
Derek Nickerson
NPI 1265895619
$4,878.28
in general payments reported to CMS, 2019-2025
23 companies · $877 in 2025
The $877 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $692 · 2021: $377 · 2022: $759 · 2023: $764 · 2024: $1,408 · 2025: $877.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,050.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,049.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $791.10 | 2019-2025 | |
| Pfizer INC. | $574.80 | 2021-2025 | |
| Genzyme Corporation | $495.18 | 2022-2025 | |
| Lilly USA, LLC | $444.05 | 2019-2025 | Taltz, Zepbound, Olumiant |
| Regeneron Healthcare Solutions, INC. | $347.17 | 2019-2025 | Libtayo, Dupixent |
| Janssen Biotech, INC. | $312.78 | 2021-2025 | Tremfya, Remicade, Stelara |
| Galderma Laboratories, L.P. | $235.56 | 2021-2025 | Nemluvio |
| Arcutis Biotherapeutics, INC. | $232.27 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $232.06 | 2022-2025 | Adbry, Anzupgo |
| Incyte Corporation | $224.01 | 2022-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $211.13 | 2024 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $175.05 | 2019-2025 | Odomzo, Blu-U |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $122.62 | 2019 | |
| Celgene Corporation | $104.80 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.39 | 2022-2024 | Spevigo |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $64.21 | 2024-2025 | Bimzelx |
| Amgen INC. | $62.84 | 2022-2024 | Otezla |
| Revance Therapeutics, INC. | $48.46 | 2024 | Daxxify |
| Dermavant Sciences, INC. | $33.13 | 2023-2024 | Vtama |
| Krystal Biotech INC | $24.66 | 2023 | Vyjuvek |
| Vyne Pharmaceuticals INC. | $21.74 | 2021 | |
| Acera Surgical, INC. | $20.92 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.35 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Nickerson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.